The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …

Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine
kinase, has served as a paradigm for successful application of molecularly targeted cancer …

Myeloid neoplasms and acute leukemias derive from the clonal expansion of hematopoietic
cells driven by somatic gene mutations. Although assessment of morphology plays a crucial …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …

For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and
acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …

Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …

From the laboratory perspective, effective management of patients with chronic myeloid
leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential …

The treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) has
been a model for cancer therapy development. Though most patients with CML have a …

Outcomes for patients with chronic myeloid leukemia (CML) have substantially improved
due to advances in drug development and rational treatment intervention strategies. Despite …